NCT07567001ClinicalTrials.gov

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.

Diese Studie kontaktieren

Kurz gefasst

Phase 35.610 Teilnehmende gesucht838 Studienzentren27 Länder

Kategorien

Herz-Kreislauf71%Endokrin und metabolisch29%

In 1 Register registriert

ClinicalTrials.govNCT07567001Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert letzten Monat

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2026-05-05; recorded start 2026-05-11
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Present: Uses blinding (masking)A masking level is recorded in the record
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 333 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 2 conditions.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding20/20
Quadruple-blind
Control arm13/15
Placebo / sham control arm
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
Multi-centre8/8
Multi-centre: 839 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 5,610 participants (target), run at 838 sites, across 27 countries.

How this score is built

Enrolment36/40
5,610 participants (target)
Site count25/25
839 sites
Country count15/15
27 countries
Planned duration8/10
Planned over about 40 months
Sponsor scale9/10
Novo Nordisk A/S has led 320 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.

Erkrankungen

Obesity
Heart Failure

Eignung

Eignung
Geschlecht	Alle
Alter	18 Years – Kein Höchstalter
Gesunde Freiwillige	Nein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Body Mass Index (BMI) greater than or equal to (\>=) 30 kilograms per square metre (kg/m\^2) at screening. * Diagnosis of HF with New York Heart Association (NYHA) class II-IV and in stable condition at screening, at the discretion of the investigator. For participants with Type 2 Diabetes (T2D) at screening: \- Diagnosed with T2D \>= 30 days before screening. Exclusion Criteria: * MI, stroke, unstable angina pectoris or worsening HF leading to either hospitalization or intravenous loop diuretics within 30 days prior to the day of screening and until randomization. * HF due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, Chagas cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, or uncorrected primary valve disease of moderate or severe degree. * Severe pulmonary disease including primary pulmonary hypertension, chronic pulmonary embolism, or severe chronic obstructive pulmonary disease (COPD) defined as: * requiring home oxygen; or - ongoing oral corticosteroid therapy; or - hospital for COPD Exacerbation within 12 months prior to screening. * Any other condition judged by the investigator to be the cause of HF symptoms (e.g., anaemia, hypothyroidism). Glycaemia-related: * History of type 1 diabetes. * Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or who, at the time of screening, are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Glycated haemoglobin (HbA1c) greater than (\>) 10 percent (%) (86 \[millimoles per mole\] mmol/mol) as measured by local or central laboratory at screening.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
Studientyp	Interventionell
Phase	Phase 3
Zuteilung	Randomisiert
Interventionsmodell	PARALLEL
Primäres Ziel	TREATMENT
Verblindung	QUADRUPLE (4)
Teilnahme	5.610 Teilnehmende gesucht

Sponsor und Mitwirkende

Novo Nordisk A/S Sponsor

Studienarme und Interventionen

NNC0487-0111EXPERIMENTAL
Participants will receive NNC0487-0111 subcutaneously (s.c.) in a dose escalating manner once weekly.
PlaceboPLACEBO_COMPARATOR
Participants will receive placebo matched to NNC0487-011 s.c. once weekly.

Interventionen

Arzneimittel NNC0487-0111
NNC0487-011 will be administered subcutaneously.
Arzneimittel Placebo
Placebo (matched to NNC0487-011) will be administered subcutaneously.

Endpunkte

Primärer Endpunkt
Time to first occurrence of a composite Heart Failure (HF) endpoint consisting of cardiovascular (CV) death
Measured in days.
Zeitrahmen From baseline (week 0) to 165 weeks
Primärer Endpunkt
Time to first occurrence of a composite HF endpoint consisting of HF hospitalisation or urgent HF visit
Measured in days.
Zeitrahmen From baseline (week 0) to 165 weeks
Sekundärer Endpunkt
Time to first occurrence of a composite HF and Major Adverse Cardiovascular Events (MACE) end-point consisting of: CV death, HF hospitalisation or urgent HF visit, Nonfatal Myocardial Infraction (MI), Nonfatal stroke
Measured in days.
Zeitrahmen From baseline (week 0) to 165 weeks
Sekundärer Endpunkt
Change in Clinical Summary Score of the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) for participants with baseline KCCQ-CSS score less than (<) 80 points
Measured as score on scale. KCCQ measures Health-Related Quality of Life (HRQOL). Score ranges from 0 to 100, with 0 as the lowest score and 100 as the highest score. Higher scores indicate better health status, fewer symptoms and greater disease-specific HRQoL.
Zeitrahmen From baseline (week 0) to week 52
Sekundärer Endpunkt
Change in estimated Glomerular Filtration Rate (eGFR) (creatinine and cystatin C-based Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] 2021) for participants with baseline eGFR< 60 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2)
Measured as mL/min/1.73 m\^2.
Zeitrahmen From baseline (week 0) to week 78
Sekundärer Endpunkt
Time to all-cause death
Measured in days.
Zeitrahmen From baseline (week 0) to 165 weeks

Daten

Daten
Startdatum	11. Mai 2026 (tatsächlich)
Primärer Abschluss	23. Juli 2029 (geschätzt)
Abschluss	15. August 2029 (geschätzt)
Erstveröffentlichung	5. Mai 2026 (tatsächlich)
Zuletzt aktualisiert	18. August 2026
Ergebnisse veröffentlicht	Im Registereintrag nicht angegeben
Status zuletzt bestätigt	August 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

530 Studienzentren rekrutieren

Argentina

Argentina
Einrichtung	Stadt	Bundesland oder Region	Status
Cardiología Hospital J. M. Ramos Mejia	Buenos Aires		Rekrutierung noch nicht begonnen
Fundación Respirar	Buenos Aires		Rekrutiert
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli	Buenos Aires		Rekrutiert
CEDIC Centro de Investigación Clínica	CABA		Rekrutierung noch nicht begonnen
Glenny Corp. S.A	CABA		Rekrutiert
CEMEDIC	CABA	Buenos Aires	Rekrutiert
Centro de Investigaciones Metabólicas	Capital Federal	Buenos Aires	Rekrutiert
Cardiología Palermo	City of Buenos Aires	Buenos Aires	Rekrutiert
CardiaMet	Ciudad Autonoma de Buenos Aires	Buenos Aires	Rekrutiert
Clínica Privada Velez Sarsfield	Córdoba		Rekrutiert
Centro Médico Luquez	Córdoba		Rekrutiert
Instituto de Investigaciones Clínicas Córdoba	Córdoba		Rekrutiert
Sanatorio Esperanza	Esperanza, Santa Fe		Rekrutiert
Hospital Español de Mendoza	Godoy Cruz, Mendoza	Mendoza Province	Rekrutiert
Centro Medico Capital	La Plata, Buenos Aires		Rekrutiert
Centro Médico CIMEL	Lanús Este	Buenos Aires	Rekrutiert
Hospital Universitario Austral - Instituto de Cardiologia	Pilar	Buenos Aires	Rekrutiert
Instituto Especialidades de la Salud Rosario	Rosario	Santa Fe Province	Rekrutiert
INECO Neurociencias Oroño	Rosario	Santa Fe Province	Rekrutiert
CAICI	Rosario		Rekrutiert
Instituto de Investigaciones Clínicas Rosario	Rosario	Santa Fe Province	Rekrutiert
Centro Cardiovascular Salta	Salta		Rekrutierung noch nicht begonnen
Instituto de Investigaciones de Patologías Respiratorias	San Miguel de Tucumán		Rekrutiert
CMC Cardiología Sociedad Simple	San Miguel de Tucumán		Rekrutiert
Instituto de Investigaciones Clinicas San Nicolás	San Nicolás		Rekrutiert
CEDIR - Centro de diagnóstico y rehabilitación Santa Fe	Santa Fe		Rekrutiert
Centro de Investigaciones Clinica Baigorria	Santa Fe		Rekrutiert
Centro de investigaciones Clinicas del Litoral	Santa Fe		Rekrutiert
MIT Medicina, Investigación y tratamiento	Santa Rosa, La Pampa		Rekrutiert

Australia

Australia
Einrichtung	Stadt	Bundesland oder Region	Status
Nightingale Research Adelaide	Adelaide	South Australia	Rekrutiert
Flinders Medical Centre - Cardiology Department	Bedford Park	South Australia	Rekrutierung noch nicht begonnen
Canberra Hospital - Clinical Trials Unit	Canberra	Australian Capital Territory	Rekrutierung noch nicht begonnen
Heart of Australia	Chelmer	Queensland	Rekrutiert
The Prince Charles Hospital - Cardiology Clinical Research Centre	Chermside	Queensland	Rekrutiert
Lyell McEwin Hospital - Clinical Trials Unit	Elizabeth Vale	South Australia	Rekrutiert
Nightingale Research Victoria	Frankston	Victoria	Rekrutiert
Adrian Costa Clinical Trials Centre	Geelong	Victoria	Rekrutiert
Royal Hobart Hospital - Cardiology Department	Hobart	Tasmania	Rekrutiert
Baker-HeartWest - Hoppers Crossing	Hoppers Crossing	Victoria	Rekrutiert
Life Clinical Research	Ipswich	Queensland	Rekrutiert
Advara HeartCare Joondalup	Joondalup	Western Australia	Rekrutiert
Advara HeartCare Leabrook	Leabrook	South Australia	Rekrutiert
Sydney Cardiometabolic Centre	Liverpool	New South Wales	Rekrutiert
Core Research Group	Milton	Queensland	Rekrutiert
Advara HeartCare Mulgrave	Mulgrave	Victoria	Rekrutiert

Brazil

Brazil
Einrichtung	Stadt	Bundesland oder Region	Status
Jmf Clínica Do Coração Ltda	Aracaju		Rekrutiert
CCIH-Consultoria em Controle de Infecção Hospitalar Ltda	Belo Horizonte	Minas Gerais	Rekrutiert
Grupo AngioKormann	Blumenau	Santa Catarina	Rekrutierung noch nicht begonnen
Associação Lar São Francisco de Assis na Providência de Deus - Bragança Paulista	Bragança Paulista	São Paulo	Rekrutiert
Synvia Laboratorios E Toxicologia Ltda	Campinas	São Paulo	Rekrutiert

788 weitere Studienzentren sind im Registereintrag aufgeführt.

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

18. August 2026
Studienzentrum entfernt
1 site removed (838 total)
839838

https://xmedica.io/trials/ctgov/NCT07567001